Welp Magazine

Muse Glimmer: Inside Zuckerberg’s Push for ‘Superintelligence for Everyone’

12 hours ago

Editorial tech illustration of a glowing translucent AI brain/network sphere labeled subtly with light particles, breaking apart into open, freely distributed nodes across a world map background, in a modern blue-and-white corporate

Buy an Online Business in 2026: Why Proof Is Now Worth More Than Potential

2 days ago

Every entrepreneur has had this thought at some point: I would rather buy an online business than spend three years building one from nothing. In 2026, that thought is worth taking seriously,

ManyChat AI Agents Are Automating DMs for a Million Businesses

Featured image DALL-E prompt: A sleek, modern flat-illustration of a glowing AI

IBM Quantum Computing Revenue Expected by 2028, CEO Says

DALL-E prompt: Editorial photograph of a modern quantum computing lab, a golden

Business

Freehand AI Wants to Replace Manual Invoice Reviews With Autonomous Finance Agents

For decades, accounts payable has remained one of the least modernized functions inside large enterprises. While procurement systems and ERP platforms have become increasingly

2 weeks ago

Stripe OpenRouter Deal: Inside the $10 Billion Bet to Own AI’s Toll Booth

Stripe is in talks to buy OpenRouter for $10 billion, a bold move to control AI model routing and billing. Here's what it means

2 weeks ago

Helsing AI Defense Startup Raises $1.8 Billion (2026)

Europe just handed its biggest defense check yet to a company that did not exist five years ago. The Helsing AI defense startup has

4 weeks ago

Inside the Apple-OpenAI Legal Battle Over Trade Secrets

Featured image DALL-E prompt: Editorial illustration for a tech news article: two sleek corporate skyscrapers facing each other at dusk, one with a subtle

4 weeks ago

Insilico Medicine AI drug rentosertib for IPF

Insilico Medicine’s AI Drug Rentosertib Reaches Phase III for IPF (2026)

What the Insilico Medicine AI Drug Rentosertib Does The Insilico Medicine AI drug rentosertib is moving into Phase III human trials, targeting idiopathic pulmonary

1 month ago